Men with Low-Risk Prostate Cancer Face Lower All-Cause Mortality vs. Cancer-Free Men
the Cancer Therapy Advisor take:
Men with low-risk prostate cancer (PCa) face lower all-cause mortality compared to PCa-free men due to lower cardiovascular mortality.
Additionally, men with intermediate or high risk face substantial death risk regardless of Charlson comorbidity index (CCI).
These results were part of a recent study published in BJU International which looked at patient data gathered from PCBase Sweden. Mieke van Hemelrijck, PHD, and fellow researchers at King’s College London in the UK observed 57,187 men diagnosed with localized PCa between 1997 to 2009 as well as 114,374 age- and county-matched PCa-free control men.
They found that in men with low-risk PCa, all-cause mortality after 10 years was 18 percent compared to corresponding men without PCa who were at 21 percent, with 31 percent of patients dying from CVD compared to 37 percent, respectively.
In low-risk men, PCa was the third most common cause of death after cardiovascular disease and other cancers. In men with intermediate and high-risk localized PCa, their disease was the most common cause of death.
Men with low-risk PCa face lower all-cause mortality compared to PCa-free men.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Radiation Therapy Increases 5-year Rate of Cardiac Events in Small-cell Lung Cancer
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Pazopanib: Where Does It Stand as Adjuvant Therapy in Localized RCC?
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC